{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:23:01Z","timestamp":1784262181287,"version":"3.55.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","doi-asserted-by":"publisher","award":["223S215"],"award-info":[{"award-number":["223S215"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jdiacomp.2025.109063","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T11:26:21Z","timestamp":1745925981000},"page":"109063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effects of empagliflozin and dapagliflozin, SGLT2 inhibitors, on miRNA expressions in diabetes-related cardiovascular damage in rats"],"prefix":"10.1016","volume":"39","author":[{"given":"Humeysa","family":"Kiyak-Kirmaci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse Nur","family":"Hazar-Yavuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif Beyzanur","family":"Polat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Alsaadoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem Tugce","family":"Cilingir-Kaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanife Serife","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice Kubra","family":"Elcioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2025.109063_bb0005","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1038\/s41467-023-38148-7","article-title":"Identification of biomarkers for glycaemic deterioration in type 2 diabetes","volume":"14","author":"Slieker","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0010","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-022-01512-w","article-title":"The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management","volume":"21","author":"Xu","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0015","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3390\/medicina55070395","article-title":"Type 2 diabetes and cardiovascular factors contrasted with fibrinolysis disorders in the blood of patients with peripheral arterial disease","volume":"55","author":"Wiecz\u00f3r","year":"2019","journal-title":"Medicina"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0020","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4103\/ajm.ajm_53_20","article-title":"Pathophysiology of diabetes: an overview","volume":"10","author":"Banday","year":"2020","journal-title":"Avicenna J Med"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0025","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12933-022-01516-6","article-title":"Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management","volume":"21","author":"Ma","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0030","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-70708-5","article-title":"Effects of empagliflozin and target-organ damage in a novel rodent model of heart failure induced by combined hypertension and diabetes","volume":"10","author":"Kr\u00e4ker","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0035","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12933-019-0964-4","article-title":"Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet\/streptozotocin-induced diabetic rats","volume":"18","author":"Shao","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0040","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12933-022-01627-0","article-title":"Effect of dapagliflozin on the prognosis of patients with acute myocardial infarction undergoing percutaneous coronary intervention","volume":"21","author":"Zhu","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0045","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s13300-022-01237-9","article-title":"Beyond the glycaemic control of dapagliflozin: microangiopathy and non-classical complications","volume":"13","author":"Bellido","year":"2022","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12216798","article-title":"Current role of SLGT2 inhibitors in the management of the whole spectrum of heart failure: focus on dapagliflozin","volume":"12","author":"Escobar","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0055","article-title":"Comparison of cardiovascular outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes: a meta-analysis","volume":"14","author":"Memon","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0060","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-13875-2","article-title":"Circulating miR-19b and miR-181b are potential biomarkers for diabetic cardiomyopathy","volume":"7","author":"Copier","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2019.03.008","article-title":"Post-transcriptional markers associated with clinical complications in type 1 and type 2 diabetes mellitus","volume":"490","author":"Massaro","year":"2019","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106035","article-title":"Current and future therapeutic perspective in chronic heart failure","volume":"175","author":"Mascolo","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e07452","article-title":"Alkaloidal extract from Zanthoxylum zanthoxyloides stimulates insulin secretion in normoglycemic and nicotinamide\/streptozotocin-induced diabetic rats","volume":"7","author":"Kyei-Barffour","year":"2021","journal-title":"Heliyon"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0080","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.biopha.2017.07.129","article-title":"Epigallocatechin-3-gallate protects against diabetic cardiomyopathy through modulating the cardiometabolic risk factors, oxidative stress, inflammation, cell death and fibrosis in streptozotocin-nicotinamide-induced diabetic rats","volume":"94","author":"Othman","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.120232","article-title":"Arjunolic acid downregulates elevated blood sugar and pro-inflammatory cytokines in streptozotocin (STZ)-nicotinamide induced type 2 diabetic rats","volume":"289","author":"Aamir","year":"2022","journal-title":"Life Sci"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0090","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41443-020-00356-w","article-title":"Exercise and caloric restriction improve cardiovascular and erectile function in rats with metabolic syndrome","volume":"33","author":"\u00c7evikelli-Yakut","year":"2020","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21062128","article-title":"Cardiac miRNA expression and their mRNA targets in a rat model of prediabetes","volume":"21","author":"S\u00e1ghy","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0100","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1440-1681.2012.05724.x","article-title":"Rosiglitazone, a peroxisome proliferator-activated receptor \u03b3 stimulant, abrogates diabetes-evoked hypertension by rectifying abnormalities in vascular reactivity","volume":"39","author":"El-Bassossy","year":"2012","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0105","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/aps.2017.50","article-title":"Resveratrol alleviates diabetic cardiomyopathy in rats by improving mitochondrial function through PGC-1\u03b1 deacetylation","volume":"39","author":"Fang","year":"2018","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0110","article-title":"The study evaluating the effect of empagliflozin and dapagliflozin on miR-133a expression and oxidative stress in the rat heart induced by streptozotocin\/nicotinamide","volume":"28","author":"Kiyak-Kirmaci","year":"2024","journal-title":"J Res Pharmacy"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0115","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12933-021-01312-8","article-title":"Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGF\u03b21\/Smad signaling","volume":"20","author":"Zhang","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0120","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4745389","article-title":"Lactobacillus plantarum and inulin: therapeutic agents to enhance cardiac ob receptor expression and suppress cardiac apoptosis in type 2 diabetic rats","volume":"2020","author":"Sefidgari-Abrasi","year":"2020","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0125","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.tem.2015.08.001","article-title":"The IL-1 pathway in type 2 diabetes and cardiovascular complications","volume":"26","author":"Herder","year":"2015","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0130","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s12906-023-04114-5","article-title":"Flavonoid compound from Agrimonia pilosa Ledeb improves adipose insulin resistance by alleviating oxidative stress and inflammation","volume":"23","author":"Guo","year":"2023","journal-title":"BMC Complement Med Ther"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0135","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3390\/pharmaceutics15030965","article-title":"SGLT2 inhibitor—dapagliflozin attenuates diabetes-induced renal injury by regulating inflammation through a CYP4A\/20-HETE signaling mechanism","volume":"15","author":"Dia","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0140","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.biopha.2016.12.044","article-title":"Quercetin ameliorates oxidative stress, inflammation and apoptosis in the heart of streptozotocin-nicotinamide-induced adult male diabetic rats","volume":"86","author":"Roslan","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0145","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/403291","article-title":"Cardioprotective activity of Pongamia pinnata in streptozotocin-nicotinamide induced diabetic rats","volume":"2015","author":"Badole","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0150","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/1472-6882-12-264","article-title":"Hypoglycemic and hypolipidemic effects of Bersama engleriana leaves in nicotinamide\/streptozotocin-induced type 2 diabetic rats","volume":"12","author":"Pierre","year":"2012","journal-title":"BMC Complement Altern Med"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0155","doi-asserted-by":"crossref","first-page":"7326","DOI":"10.1038\/s41598-022-11033-x","article-title":"FGF21-FGFR4 signaling in cardiac myocytes promotes concentric cardiac hypertrophy in mouse models of diabetes","volume":"12","author":"Yanucil","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0160","doi-asserted-by":"crossref","first-page":"172","DOI":"10.31024\/ajpp.2019.5.1.25","article-title":"Evaluation of dapagliflozin in diabetes induced endothelial dysfunction in rats","volume":"5","author":"Kumar","year":"2019","journal-title":"Asian J Pharmacy Pharmacol"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.979300","article-title":"Effect of sulfasalazine on endothelium-dependent vascular response by the activation of Nrf2 signalling pathway","volume":"13","author":"Sonmez","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0170","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.bbrc.2016.02.065","article-title":"MicroRNA-9 inhibits hyperglycemia-induced pyroptosis in human ventricular cardiomyocytes by targeting ELAVL1","volume":"471","author":"Jeyabal","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-021-01245-2","article-title":"MicroRNAs and long non-coding RNAs in the pathophysiological processes of diabetic cardiomyopathy: emerging biomarkers and potential therapeutics","volume":"20","author":"Jakubik","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21010358","article-title":"Oxidative stress-responsive microRNAs in heart injury","volume":"21","author":"Kura","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0185","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6143129","article-title":"Subclinical detection of diabetic cardiomyopathy with microRNAs: challenges and perspectives","volume":"2016","author":"Le\u00f3n","year":"2016","journal-title":"J Diabetes Res"},{"issue":"2","key":"10.1016\/j.jdiacomp.2025.109063_bb0190","first-page":"1","article-title":"GAS5 regulates diabetic cardiomyopathy via miR-221-3p\/p27 axis-associated autophagy","volume":"23","author":"Chen","year":"2021","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0195","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41418-017-0047-6","article-title":"Diabetes induces the activation of pro-ageing miR-34a in the heart, but has differential effects on cardiomyocytes and cardiac progenitor cells","volume":"25","author":"Fomison-Nurse","year":"2018","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0200","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.2337\/db11-0478","article-title":"miR-146a-mediated extracellular matrix protein production in chronic diabetes complications","volume":"60","author":"Feng","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2020.610561","article-title":"MiR-223-3p in cardiovascular diseases: a biomarker and potential therapeutic target","volume":"7","author":"Zhang","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105941","article-title":"MicroRNA targets and biomarker validation for diabetes-associated cardiac fibrosis","volume":"174","author":"Jin","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jdiacomp.2025.109063_bb0215","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/cbdd.14104","article-title":"Upregulation of miR-144-3p alleviates doxorubicin-induced heart failure and cardiomyocytes apoptosis via SOCS2\/PI3K\/AKT axis","volume":"101","author":"Zhang","year":"2023","journal-title":"Chem Biol Drug Des"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725001163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725001163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:05:59Z","timestamp":1762362359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872725001163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1056872725001163"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109063","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of empagliflozin and dapagliflozin, SGLT2 inhibitors, on miRNA expressions in diabetes-related cardiovascular damage in rats","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025","name":"copyright","label":"Copyright"}],"article-number":"109063"}}